RNAZ · Transcode Therapeutics, Inc.
$2.28
-0.06 (-2.56%)
At close · Aug 27
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed Aug 14, 2026
Market Cap
$39.62M
Shares
16.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$34.66M
-106.9%
FY2025
Diluted EPS
-$52.59
+96.1%
FY2025
Operating Cash Flow
-$19.52M
-46.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $17.44M | $13.42M | $9.71M | $12.26M | $10.23M | $2.75M | $284.46K | |
| $7.92M | $5.77M | $5.95M | $7.15M | $8.4M | $3.4M | $442.15K | |
| $34.43K | $13.44K | $90.89K | $123.48K | $98.61K | $42.47K | $0 | |
| $45.13M | $27.98M | $15.66M | $19.42M | $18.63M | $6.15M | $726.6K | |
| -$45.13M | -$27.98M | -$15.66M | -$19.42M | -$18.63M | -$6.15M | -$726.6K | |
| — | $6616 | $26.81K | $55.9K | $31.99K | $95.07K | $394.57K | |
| $222.96K | $79.2K | $684 | $5285 | $20.41K | $664 | $136 | |
| $2.76M | -$6.45M | -$1.09M | $872.42K | $1.07M | -$692.26K | -$1.62M | |
| — | -$34.44M | -$16.75M | — | — | — | — | |
| — | $226.07K | $0 | $0 | $0 | $53.05K | $0 | |
| -$42.83M | -$34.66M | -$16.75M | -$18.55M | -$17.56M | -$6.84M | -$2.34M | |
| -$46.28M | -$36.27M | -$16.79M | -$18.55M | — | — | — | |
| USD/shares | -$5.75 | -$52.59 | -$1,336.63 | -$95,732.28 | -$1,000,497.96 | -$598,752.00 | -$376,992.00 |
| USD/shares | -$5.75 | -$52.59 | -$1,336.63 | -$95,732.28 | -$1,000,497.96 | -$598,752.00 | -$376,992.00 |
| shares | — | 689.71K | 12.56K | 193.7143 | 17.5563 | 11.3986 | 6.2719 |
| shares | — | 689.71K | 12.56K | 193.7143 | 17.5563 | 11.3986 | 6.2719 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.78×
EV/EBIT
—
Peer median 12.50×
P/E (TTM)
—
Peer median 5.80×
Peer medians compare against the 276 similar-size Biotechnology companies (of 534 listed).